3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Brenner Tumor
4
Colorectal Neoplasms
3
Colonic Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Stroke
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Lymphoid Interstitial Pneumonia
1
Kidney Failure, Chronic
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Endometrial Neoplasms
1
Diabetes Mellitus
1
Coronary Artery Disease
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Imatinib Mesylate
19
Sunitinib
9
nilotinib
4
ripretinib
3
regorafenib
2
masitinib
2
tanespimycin
1
famitinib
1
avapritinib
1
Sodium Chloride
1
Midazolam
1
Mastectomy, Segmental
1
Immunoglobulin G
1
IDRX-42
1
Fentanyl
1
Disulfides
1
Carnitine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gastrointestinal Stromal Tumors
×
Disulfides
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts